The PD-1/PD-L1 immunotherapy based on bladder cancer further demonstrated that high levels of FABP4, CDR2L, and FSTL3 expression were associated with a poor response to immunotherapy, confirming the applicability of the associated immune dysregulation across various tissues and diseases. The gene discussed is CDR2L; the disease is urinary bladder cancer.